Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2013-003884-71-NL
EUCTR2013-003884-71-NL
Active, not recruiting
Phase 1

A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409) - TOPAZ

Genzyme Corporation0 sites1,248 target enrollmentAugust 11, 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsRelapsing-remitting multiple sclerosisMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
DrugsLemtrada

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Relapsing-remitting multiple sclerosis
Sponsor
Genzyme Corporation
Enrollment
1248
Status
Active, not recruiting
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 11, 2014
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\- Patient has completed at least 48 months of the Extension Study CAMMS03409
  • •\- Signed written informed consent form
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 1248
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •\- Patient participating in another investigational interventional study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409Relapsing-remitting multiple sclerosisMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2013-003884-71-CZGenzyme Corporation1,248
Active, not recruiting
Phase 1
Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409
EUCTR2013-003884-71-ITGenzyme Corporation799
Active, not recruiting
Phase 1
Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409
EUCTR2013-003884-71-DKGenzyme Corporation1,248
Active, not recruiting
Phase 1
Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409Relapsing-remitting multiple sclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2013-003884-71-ESGenzyme Corporation1,062
Active, not recruiting
Phase 1
Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409
EUCTR2013-003884-71-HRGenzyme Corporation1,062